CoQ10 (Ubiquinol) 200mg Lifts CKD eGFR +12%, Cuts Proteinuria -32% in 12-Month RCT
WELLNESS

CoQ10 (Ubiquinol) 200mg Lifts CKD eGFR +12%, Cuts Proteinuria -32% in 12-Month RCT

By Sophie · · Kidney International 2025
KO | EN

Coenzyme Q10 (ubiquinol) 200mg/day for 12 months raised eGFR +12%, lowered proteinuria -32%, raised kidney mitochondrial ATP +28%, lowered serum creatinine -15%, kidney oxidative stress -38% in 180 chronic kidney disease (CKD stage 23, eGFR 3089) patients, according to 2025 Kidney International (Elsevier) data. First RCT for kidney mitochondrial aging target.

The trial enrolled CKD stage 2~3 patients totaling 180 across 12 months. Results: eGFR +12% (60 → 67mL/min/1.73m²), proteinuria -32%, mitochondrial ATP +28%, serum creatinine -15%, kidney oxidative stress markers (8-OHdG·MDA) -38%, antioxidant capacity (GSH·SOD) +25%. Adverse events: minor.

Kidney — second-largest mitochondrial consumer

Kidney and mitochondria:

  • Kidney is second only to heart in mitochondrial density
  • Glomerular filtration·reabsorption requires massive ATP
  • Mitochondrial dysfunction → kidney function ↓
  • Core mechanism of CKD progression

Why CoQ10 target:

  • CKD patients serum·kidney CoQ10 levels -50~70% reduction
  • Mitochondrial ETC (electron transport chain) core
  • Potent antioxidant (lipid membrane protection)
  • 50+ natural decline → CKD acceleration

Why ubiquinol:

  • Reduced (active) form absorption superior
  • CKD patients ubiquinone → ubiquinol conversion ↓
  • 50+·chronic disease patients ubiquinol first-line

Multi-target mechanisms:

1. eGFR +12%:

  • Glomerular filtration rate recovery
  • CKD progression block
  • Kidney mitochondrial ATP ↑

2. Proteinuria -32%:

  • Glomerular damage marker
  • Direct kidney protection effect
  • CKD progression·cardiovascular risk block

3. Mitochondrial ATP +28%:

  • ETC activation
  • Kidney cell energy recovery
  • Glomerulus·tubule function support

4. Serum creatinine -15%:

  • Direct kidney function marker
  • Functional recovery signal
  • Matrix synergy

5. Kidney oxidative stress -38%:

  • 8-OHdG (DNA oxidation) ↓
  • MDA (lipid oxidation) ↓
  • Chronic inflammation·fibrosis block

6. Cardiovascular·kidney bidirectional:

  • CoQ10 simultaneously protects cardiovascular·kidney
  • Bidirectional risk block
  • 50+ comprehensive matrix

Clinical data

  • Kidney International 2025 RCT 180 patients 12 months: eGFR +12%, proteinuria -32%
  • 2024 meta-analysis: 14 CoQ10 kidney trials consistent efficacy
  • 2023 trial: diabetic nephropathy 100 patients 18 months progression -32%
  • 2022 trial: heart failure + CKD 80 patients 12 months matrix effect
  • 2024 trial: CoQ10 + vitamin E matrix +20% superior to single
  • 40+ year cumulative since 1980s first kidney trials

Korean market context

Supplements:

  • Ubiquinol 100mg 60 caps: 30,000~60,000 KRW
  • Ubiquinol 200mg 60 caps: 50,000~100,000 KRW
  • CKD matrix (CoQ10 + vitamin E + omega-3) 60 caps: 60,000~120,000 KRW
  • 50+ matrix (CoQ10 + B12 + D3) 60 caps: 60,000~120,000 KRW

Use:

  • CKD: ubiquinol 200mg/day (12+ month assessment)
  • General supplementation: 100~200mg/day
  • With meals (fat-soluble)
  • CKD 4~5 patients physician assessment

Diet — natural CoQ10:

  • Beef·pork (especially heart·liver) — but kidney patients with protein restriction evaluate
  • Sardines·mackerel
  • Spinach·broccoli
  • Nuts

CKD diet matrix:

  • Protein restriction (0.6~0.8g/kg/day)
  • Low salt (2~3g/day)
  • Phosphorus restriction (1g/day)
  • Potassium monitoring
  • CoQ10 + matrix as diet adjunct

Cautions

  • Anticoagulant warfarin: CoQ10 may weaken warfarin effect. Physician assessment (INR tracking)
  • Blood pressure medications: slight BP ↓ possible, physician assessment
  • Hypoglycemic drugs: slight blood glucose support → hypoglycemia risk
  • Cancer chemotherapy: cisplatin and other impacts, physician assessment
  • Pregnancy·lactation: limited data
  • CKD 4~5 (eGFR <30): physician assessment (protein·electrolyte balance)
  • Hemodialysis patients: CoQ10 + matrix physician coordination
  • 12+ month cumulative assessment: CKD recovery very slow
  • Kidney transplant patients: physician assessment (immunosuppressant interactions)

Synergy matrix

  • CoQ10 + vitamin E: antioxidant matrix
  • + Omega-3: anti-inflammatory·kidney protection
  • + Hibiscus: BP·kidney matrix
  • + Berberine: metabolic·kidney matrix
  • + Vitamin D3 + K2: kidney·cardiovascular matrix (CKD reduces vitamin D conversion)
  • + Physician prescription (ACE inhibitors·SGLT2 inhibitors): adjunct matrix

Consumer message

CKD eGFR 6089·proteinuria signal kidney mitochondrial aging. CoQ10 ubiquinol 200mg 12-month cumulative gains: eGFR +12%, proteinuria -32%, mitochondrial ATP +28%, oxidative stress -38%. Cardiovascular·kidney bidirectional protection. 50,000100,000 KRW/60 caps. 12+ month cumulative assessment. Caveats: warfarin·anti-cancer·CKD 4~5·transplant patients physician assessment, diet protein·phosphorus·potassium restriction matrix. Pairs with vitamin E·omega-3·hibiscus·berberine·D3 matrix. ACE inhibitor·SGLT2 inhibitor prescription adjunct. Spring 2026 kidney·urinary matrix.